114 results on '"Ji, Niannian"'
Search Results
2. Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial
3. ESTABLISHMENT OF A DOUBLE-HUMANIZED MOUSE MODEL USING PATIENT-DERIVED XENOGRAFT BLADDER CANCER TUMOR CELL LINE AND HUMAN γδ T-CELLS
4. Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer
5. 925 Chemokine malfunction: CCL2-nitration mediated dysfunction of T cells in bladder cancer
6. Figure S3 from γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer
7. Data from γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer
8. Supplementary Table S1 from γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer
9. Supplementary Figure Legends from γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer
10. Data from Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer
11. Supplementary Figures S1-6 from Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer
12. Supplementary Table S1 from Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer
13. KLRF1 , a novel marker ofCD56 bright NKcells, predicts improved survival for patients with locally advanced bladder cancer
14. Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer
15. KLRF1, a novel marker of CD56bright NK cells, predicts improved survival for patients with locally advanced bladder cancer.
16. Nitration of CCL2 disrupts the tumor-protective function of CCL2 in bladder cancer
17. γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer
18. Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial
19. 242 Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive
20. Bladder tumor ILC1s undergo Th17‐like differentiation in human bladder cancer
21. LBA02-03 A PHASE II RANDOMIZED CLINICAL TRIAL OF YOGA IN MEN WITH PROSTATE CANCER
22. ELISPOT Techniques
23. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
24. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
25. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation
26. More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases
27. 719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer
28. CCL2/CCR2 signaling protects against bladder cancer growth in a T cell dependent manner
29. CD122-selective IL-2 complexes target γδ T and NK cells to reduce tumor-promoting Th17 effects and synergize with αPD-L1 to treat primary and metastatic bladder cancer
30. Quo vadis Th1 and Th2 cells in autoimmunity and infectious diseases: Th17 cells, the new kid on the block
31. Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial
32. Selective IL-2 receptor β (CD122) targeting improves αPD-L1 immunotherapy in a metastatic bladder cancer model
33. MP57-06 SURGICALLY-INDUCED STRESS ALTERS TUMOR SURVIVAL AND RESPONSE TO ADJUVANT IMMUNOTHERAPY IN BLADDER CANCER
34. Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer
35. Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer
36. Aire is not essential for regulating neuroinflammatory disease in mice transgenic for human autoimmune-diseases associated MHC class II genes HLA-DR2b and HLA-DR4
37. Abstract 3792: Intratumoral CD56brightnatural killer cells are associated with improved survival in bladder cancer
38. Aire is not essential for regulating autoimmune pathology in mice transgenic for human autoimmune-disease associated MHC class II genes HLA-DR2b and HLA-DR4.
39. Priming with percutaneous bacillus Calmette-Guerin (BCG) prior to intravesical BCG treatment safely improves BCG-specific response in patients with bladder cancer
40. Rapamycin prevents surgery-induced T cell exhaustion in patients with bladder cancer
41. An Online Virtual Machine Placement Algorithm in an Over-Committed Cloud
42. Abstract 548: Characterization of myeloid cells in bladder cancer
43. Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE
44. Identifying biomarkers for monitoring disease progression in experimental autoimmune encephalomyelitis (THER7P.942)
45. ELISPOT Techniques.
46. Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE
47. The Kinetics of Myelin Antigen Uptake by Myeloid Cells in the Central Nervous System during Experimental Autoimmune Encephalomyelitis
48. Small Molecule Inhibitor of Antigen Binding and Presentation by HLA-DR2b as a Therapeutic Strategy for the Treatment of Multiple Sclerosis
49. Evaluation of a HLA-DR2 Inhibitor for the Treatment of MS Using Human Cellular Immunologic Models (51.6)
50. Investigating the Role of ERK2 in Peripheral T cells Function Using a Novel Transgenic Mouse Model (47.13)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.